Clinical trials: CAR T-Cell Therapy
Small Cell Lung Cancer ( SCLC ), CAR-T Cell Therapy
TC-D101 Cell Therapy for Patients With DLL3-Positive SCLC
This is a single-arm, open-label, dose-escalation clinical trial designed to evaluate the safety, tolerability, expansion, and persistence of TC-D101 CAR-T cells in patients with DLL3-positive Relapsed/Refractory primary small…
- Trial name
- NCT07246304
- Testing
- TC-D101 CAR-T
- Where
- China
- Volunteers
- 24 people
- Sponsor
- TCRCure Biopharma Ltd.
CD19 Positive, B-ALL
Metabolically Fit CD19 CAR T Cells With CD34 Selection Markers in Adults With CD19-Positive B-Cell Acute Lymphocytic Leukemia
The goal of this trial is to determine safe dosing of CD19-CD34t metabolically programmed CAR-T cell therapy in adult patients with CD19-positive B-cell acute lymphocytic leukemia (B-ALL).
- Conditions
- CD19 Positive, B-ALL, B-cell Acute Lymphocytic Leukemia, Chimeric Antigen Receptor T-cell
- Trial name
- NCT07896213
- Testing
- Fludarabine, Cyclophosphamide, Levetiracetam
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Medical University of South Carolina
Septic Shock, Acute Respiratory Distress Syndrome
CytOSorb TreatMent Of Critically Ill PatientS Registry
Registry intended to provide a data repository and reporting infrastructure for the surveillance of CytoSorb device use in real-world critical care settings, and to serve as an objective, comprehensive, and scientifically-based…
- Conditions
- Septic Shock, Acute Respiratory Distress Syndrome, Trauma, Rhabdomyolysis
- Trial name
- COSMOS (NCT05146336)
- Testing
- CytoSorb
- Where
- 28 sites in Austria, Germany and 4 more
- Volunteers
- 3,000 people
- Sponsor
- CytoSorbents, Inc
Childhood-Onset Systemic Lupus Erythematosus, Refractory SLE
CD19 CAR-T Therapy for Refractory Childhood-Onset Systemic Lupus Erythematosus
This study is evaluating the safety and potential benefits of CD19 chimeric antigen receptor T-cell (CAR-T) therapy in children and young adults with severe systemic lupus erythematosus (SLE) that began during childhood.
- Conditions
- Childhood-Onset Systemic Lupus Erythematosus, Refractory SLE, CD19 CAR-T Cell Therapy
- Trial name
- NCT07855302
- Testing
- SNUH-CD19-CAR-T Cells, Lymphodepleting Chemotherapy
- Where
- South Korea
- Volunteers
- 8 people
- Sponsor
- Seoul National University Hospital
SLE, Systemic Lupus Erythematosus (SLE)
CD19-Directed Chimeric Antigen Receptor Autologous T Cells (CART19) for Lupus
This is a single-center, single-arm, open-label phase 1/2 study of CART19 in children and young adults with refractory Systemic lupus erythematosus (SLE), including both patients diagnosed with lupus nephritis (LN) and patients…
- Conditions
- SLE, Systemic Lupus Erythematosus (SLE), CAR T Cell, CART19
- Trial name
- NCT06839976
- Testing
- CART19
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Children's Hospital of Philadelphia
Patients Followed for up to 15 Years Following Their First Dose of AUTO CAR T Cell Therapy, Multiple Myeloma
Long-term Follow-up of Patients Treated With Genetically Modified Autologous T Cells
Long-term follow-up of patients exposed to an AUTO CAR T cell therapy for up to 15 years following their first AUTO CAR T cell therapy infusion.
- Conditions
- Patients Followed for up to 15 Years Following Their First Dose of AUTO CAR T Cell Therapy, Multiple Myeloma, DLBCL, ALL, Adult and Pediatric
- Trial name
- NCT03628612
- Testing
- AUTO CAR T cell therapy
- Where
- 9 sites in United States, Spain and 1 more
- Volunteers
- 500 people
- Sponsor
- Autolus Limited
Lymphoma Diffuse Large B-cell, Leukemia and Lymphoma
Study of Allo-QuadCAR01-T, an Allogeneic CAR-T Targeting CD19/CD20, in Patients With Relapsed or Refractory B-Cell Malignancies
This study is testing Allo-QuadCAR01-T, a new off-the-shelf CAR-T therapy for people with hard-to-treat B-cell cancers. Unlike current CAR-T treatments that use a patient's own cells, this therapy uses donor cells that are ready…
- Conditions
- Lymphoma Diffuse Large B-cell, Leukemia and Lymphoma, Leukemia Relapse, Lymphoma Receiving CAR-T Therapy
- Trial name
- QUADvance (NCT07284433)
- Testing
- Cyclophosphamide (Non-IMP, Lymphodepletion), Fludarabine (Non-IMP, Lymphodepletion), Allo-QuadCAR01-T
- Where
- 13 sites in United States, Germany
- Volunteers
- 178 people
- Sponsor
- AvenCell Therapeutics, Inc.
B-Acute Lymphoblastic Leukemia, CAR-T Cell Therapy
Pre-emptive Anakinra for Cytokine Event Reduction
Objectives: The primary objective of this study will be to evaluate the impact of pre-emptive use of anakinra on the rate of severe cytokine release syndrome (CRS) following CD19-directed chimeric antigen receptor (CAR) T-cell…
- Conditions
- B-Acute Lymphoblastic Leukemia, CAR-T Cell Therapy, Cytokine Release Syndrome, Immune Effector Cell Associated Neurotoxicity Syndrome
- Trial name
- PACER (NCT06703216)
- Testing
- Anakinra (Kineret®)
- Where
- United States
- Sponsor
- Kevin McNerney
Lymphoma Nonhodgkin, Marginal Zone B Cell Lymphoma
A Phase II Study to Evaluate the Efficacy of UF-KURE19 Cells in Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas
The goal of this Phase II single-arm, open-label clinical trial is to evaluate whether UF-KURE19, an autologous CD19-directed CAR-T cell therapy manufactured t…The goal of this Phase II single-arm, open-label clinical trial is to…
- Conditions
- Lymphoma Nonhodgkin, Marginal Zone B Cell Lymphoma, Diffuse Large B Cell Lymphoma (DLBCL), Follicular B-cell Non-Hodgkin's Lymphoma
- Trial name
- NCT07713459
- Testing
- CART Infusion
- Volunteers
- 105 people
- Sponsor
- Kure Cells, INC
Relapsed Multiple Myeloma, Refractory Multiple Myeloma
INfections in Patients Treated With CAR-T
This study includes adults with multiple myeloma or B-cell lymphoma who were/will be treated with CAR-T cell therapy at the IRCCS Azienda Ospedaliero-Universitaria di Bologna.
- Conditions
- Relapsed Multiple Myeloma, Refractory Multiple Myeloma, B-Cell Non-Hodgkin Lymphoma, Bloodstream Infections
- Trial name
- IN-CART (NCT07713511)
- Where
- Italy
- Volunteers
- 290 people
- Sponsor
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
Hematopoietic Stem Cell Transplant, CAR-T Cell Therapy
Coping Skills Training for Symptom Management and Daily Steps (Step Up)
The aim of this study is to test the efficacy of a hybrid in-person and mHealth coping skills training and activity coaching intervention (Step Up), to enable HCT patients to effectively cope with symptoms (pain, fatigue, and…
- Trial name
- NCT06575712
- Testing
- Step Up, Usual Care Plus (UC+)
- Where
- United States
- Volunteers
- 177 people
- Sponsor
- Duke University
CAR T-Cell Therapy
Neuroimaging and Biomarkers of Neurotoxicity After Chimeric Antigen Receptor T-Cell Therapy
The goal of this study is to understand why some people receiving chimeric antigen receptor (CAR) T-cell therapy for cancer experience neurotoxicity.
- Trial name
- NCT07075523
- Testing
- Brain magnetic resonance imaging, neurocognitive assessments, quality of life questionnaire, biomarkers
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- University of California, San Diego
CAR T Cell, CAR T Cell Therapy
Long-Term Follow-Up of Subjects Treated With Seattle Children's Therapeutics Gene Therapy Products
Subjects exposed to gene therapy products (GTPs) may be at risk for delayed or long-term adverse events. This is a long-term follow-up (LTFU) protocol designed to evaluate the long-term safety of Seattle Children's Therapeutics…
- Trial name
- LTFU-01 (NCT07424157)
- Testing
- Long term follow up in all patients who received an SCTx gene therapy product
- Where
- United States
- Volunteers
- 500 people
- Sponsor
- Seattle Children's Hospital
ANCA Associated Vasculitis, CAR-T Cell Therapy
Study of Therapeutic Efficacy of Anti-CD19 CAR-T Cells in Children With Refractory Refractory AAV
This is an investigator-initiated trial aimed at assessing the safety and efficacy of anti-CD19 CAR-T cells in the treatment of childhood-onset refractory ANCA-Associated Vasculitis.
- Trial name
- NCT06508346
- Testing
- anti-CD19-CAR-T cells
- Sponsor
- The Children's Hospital of Zhejiang University School of Medicine
Multi-Drug Resistant Nephrotic Syndrome, CAR-T Cell Therapy
Study of Therapeutic Efficacy of Anti-CD19 CAR-T Cell Therapy in Patients With MDR-SRNS
This is an investigator-initiated trial aimed at assessing the safety and efficacy of anti-CD19 CAR-T cells in the treatment of patients with Multi-drug resistant SRNS
- Trial name
- NCT06842589
- Testing
- anti-CD19 CAR-T cells
- Sponsor
- The Children's Hospital of Zhejiang University School of Medicine
Leukemia, Hematopoetic Stem Cell Transplantation
Exercise as an Immune Adjuvant for Allogeneic Cell Therapies
This study aims to improve the treatment of blood cancer by using exercise to collect healthier immune cells from donors. Allogeneic adoptive cell therapy is a treatment where immune cells from a healthy donor are given to a…
- Conditions
- Leukemia, Hematopoetic Stem Cell Transplantation, Donor Lymphocyte Infusion, CAR T-Cell Therapy
- Trial name
- Allo-X (NCT06643221)
- Testing
- Exercise, Isoproterenol, Bisoprolol Fumarate Tablet 10 mg
- Where
- United States
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- University of Arizona
CAR-T Cell Therapy
Dual Target CAR-T Cell Treatment for Refractory Systemic Lupus Erythematosus (SLE) Patients
This is an early exploratory phase, single arm, non-randomized, open label, treatment study trial to determine the maximum tolerated dose of GC012F injection (CD19-BCMA CAR-T cells) in patients with refractory systemic lupus…
- Trial name
- NCT05858684
- Testing
- GC012F injection
- Where
- China
- Volunteers
- 18 people
- Sponsor
- RenJi Hospital
Patients With Large B-cell Lymphoma Receiving CAR-T Cell Therapy
Study on the Effect of Oral Diammonium Glycyrrhizinate in Attenuating Toxicity and Enhancing Efficacy of CAR-T Cell Therapy
The purpose of this study is to evaluate the effect of oral diammonium glycyrrhizinate in reducing toxicity and enhancing efficacy of CAR-T cell therapy in patients with large B-cell lymphoma.
- Trial name
- NCT07616271
- Testing
- Diammonium glycyrrhizinate Capsules
- Volunteers
- 21 people
- Sponsor
- Tongji Hospital
Multiple Sclerosis, CAR T Cell Therapy
MB-CART2019.1 in Refractory Multiple Sclerosis
The goal of this trial is to assess the feasibility, safety and preliminary efficacy of MB-CART2019.1 in patients with active refractory primary and secondary progressive MS.
- Trial name
- NCT07178431
- Testing
- MB-CART2019.1
- Where
- Germany
- Volunteers
- 26 people
- Sponsor
- Miltenyi Biomedicine GmbH
CAR T Cell Therapy, CD33 Positive Acute Myelogenous Leukemia
Functionally Optimized CD33 CAR-T Cell Therapy Targeting Recurrent/Refractory Acute Myeloid Leukemia
Relapsed/refractory acute myeloid leukemia (R/R AML) currently lacks effective CAR-T therapeutic agents due to the absence of tumor-specific target antigens.
- Trial name
- NCT07538713
- Testing
- Functionally optimized CD33 CAR-T
- Volunteers
- 18 people
- Sponsor
- Qi deng